INTRODUCTION {#S1}
============

Drug utilization is an important component of many research initiatives that examine the clinical and economic effectiveness of pharmacotherapy. Monitoring medications use and knowledge of prescription habits are some of the strategies recommended for containing and controlling medication cost and its effect on national budget. Interventional programs should focus on promoting rational medication prescriptions such as the use of human albumin, antimicrobials, antivirals or hyperimmune gamma globulin (IVIG) aimed at minimizing futile expenses.

The application of drug utilization monitoring likewise provides further input into utilization correlation with medication effectiveness, prescribing habits, and time dependencies.[@B1]

A globally accepted 'dose standard unit' is important for drug utilization (DU) studies, particularly if the investigations are performed in countries situated in different geographic areas and are to be compared.[@B2] The DDD is a technical unit for comparison - "the average recommended daily dose of a drug when used for its main indication".[@B3] The DDD methodology was developed in response to the necessity to convert and harmonize readily available volume data (bulk costs and prescriptions) from supply statistics of pharmacy inventory data into medically meaningful units, and to make crude estimates of the number of persons exposed to a particular drug or class of drugs.[@B2],[@B4]

Drug utilization has been defined as "the prescribing, dispensing and ingesting of drugs".[@B5] The Drug Utilization 90% (DU90%) index was introduced as a simple, inexpensive and flexible method for assessing the quality of drug prescriptions. It identifies the drugs accounting for 90% of the volume of prescribed drugs after ranking the drugs used by volume of DDD. The remaining 10% may contain specific drugs used for rare conditions in patients with a history of drug intolerance or adverse effects, complex co-morbid conditions and/or therapy prescribed by others.[@B6]

It has been recommended the DU 90% method for assessing general quality in drug prescribing[@B2]-[@B4],[@B7] habits, this index is a reliable cut-off level for pharmacoepidemiology and economic surveys, and can be considered for the elaboration of a "health cost index".[@B4] It has been advocated that the Drug Cost 90% Index (DC90%) should be included in drug utilization research studies.[@B4],[@B6],[@B7]

Drug utilization studies in the in-patient setting can provide a mechanism to assess drug prescribing trends, efficiency, and cost-effectiveness of hospital formularies and examine subpopulations for which prescribing habits may be different. In the realm of pediatric pharmacotherapy, the investigation of drug utilization is used to examine different outcomes, including the examination of prescribing trends in clinical settings, the extent to which best practices in children differ from drug monograms/labeling and adult dosing guidelines, the cost-effectiveness of hospital formularies, and the correlation between medication errors and utilization.[@B1]

The aim of this descriptive study was to analyze general medication utilization patterns and costs excluding antimicrobials prescriptions and to compare two pediatric admission units in a tertiary care university hospital.

METHODS {#S2}
=======

Rambam Health Care Campus is a 1000-bed urban tertiary care teaching hospital affiliated with the B. Rappaport Faculty of Medicine of the Technion, Israel Institute of Technology, in Haifa, Israel. In this set-up are located 2 pediatric admission units who belong to the Meyer Hospital.

Prospective data collection regarding medications used, diseases severity and patient outcome was performed in the Pediatric A and B admission units, respectively. The emergency admissions between 15:00 up to 07:59 of the next day were admitted at-random from the Pediatric Emergency Department to the admission units. Elective admission from the pediatric out-patients clinics were admitted accordingly to the following admission policy: children suffering from rheumatic or gastrointestinal diseases were admitted to the B unit. Children suffering diabetes mellitus or other endocrine diseases, lung diseases or immune deficiencies were admitted to the A unit. Other elective admissions were admitted at random to the A or B unit, respectively. The study protocol was approved by the local Ethical Commission and was registered in the NIH Clinical Trials registry with the number 00550706. Data on individual prescriptions, utilization patterns and medication costs were collected prospectively from October 15, 2007, up to April 7, 2008, in children for whom at least one medication exposure was registered.

The same observer (DO) was responsible for recording and feeding the data into the computer programs. Upon child admission, the following data were recorded on individual forms: admission date, age, gender, main admission diagnosis, medication prescriptions, delivery route, dose, starting day, and therapy ending day.

General medications were all those medications prescribed by a physician or OTC medications delivered by a nurse to admitted children. The general medications prescriptions exclude antiviral, antifungal and antimicrobial medications. The off-level indications were not taken into consideration in this study.

Exposure to a medication was considered when the child received the prescribed medication, and the nurse registered it in the individual electronic file. Prescription is the written request for a medication supply from the pharmacy.

Data collection was performed according to the prescription-point prevalence technique as described in previous publications.[@B4],[@B7],[@B8] For each admission unit, the encounter with the patient file for review was once a week (Mondays) on the same day-time if the encounter day was a fest or a holyday the encounter was performed on the next working day.

The ATC-DDD classification for each drug was obtained from the WHO Guidelines.[@B9] Medication costs were obtained from the hospital pharmacy and the computer center. Costs are presented in New Israel Shekels (NIS) (NIS1=US\$ 0.27).

The data obtained from both admission units were fed into an Excel program prepared especially for the survey and to the Prizm 3.0 Graph-Pad program for further analysis.

RESULTS {#S3}
=======

A total of 252 and 253 children were screened in this survey in Pediatric A and B. The general information data is shown in [Table 1](#T1){ref-type="table"}. During the study period no death were registered in both admission unit. In [Table 2](#T2){ref-type="table"} the admission diagnosis is depicted. [Table 3](#T3){ref-type="table"} and [4](#T4){ref-type="table"} show the DU90% and DC90% for both admission units.

###### 

General information

  --------------------------------------------------------- ----------- -----------
  Parameters                                                A           B
  Total children admitted during the study period           1,521       1,467
  Screened children (Prescription-point prevalence)         252         253
  Total admission days during the study period (26 weeks)   4,462       4,070
  Mean admission days/patient in hospital                   3.07        3.01
  Total prescriptions for the same period                   1,017       1,206
  General medications volume/patient                        8.4         10.9
  Total DDD- 26 encounters                                  2,509.63    6,110.35
  Drug Utilization Index (DU90%)- 26 encounters             2,259       5,499
  Drug Cost Index (DC90%)(NIS)-26 encounters                28,265.76   27,423.00
  --------------------------------------------------------- ----------- -----------

###### 

Admission diagnosis

  ------------------------------------ ----- -----
                                       A     B
  Cardiovascular Diseases              25    32
  Collagen Diseases and Arthropaties   4     6
  Dermatology                          4     4
  Endocrinology-Metabolism             10    9
  Gastrointestinal Diseases            35    38
  General                              19    17
  Hematology-Oncology                  12    18
  Infective Diseases                   131   108
  Invasive Diagnostic Procedures       3     2
  Lung Diseases                        49    66
  Musculoskeletal                      3     3
  Nephrology                           17    5
  Neurology                            23    42
  Ophthalmology                        1     2
  Psychiatry                           3     1
  Vascular Diseases                    1     4
  ------------------------------------ ----- -----

###### 

Define Daily Dose (DDD), Drug Utilization 90% Index (DU90%) and Drug Cost 90% Index (DC90%) for Pediatric A.

  --------------------- --------------- ---------------------- -----------
                        DDD                                    DC90% NIS
  Salbutamol            835             Clonazepam             16,211
  Clonazepam            382.82          Glucose 5%             4,307
  Ibuprofen             255.67          Acetylcysteine         2,160
  Folic acid            202.4           Lactulose              1,302
  Erythropoietin        125             Erythropoietin         900
  Ipratropium Bromide   113.54          Albumin                816
  Budesonide            92.66           Budesonide/Fenoterol   700
  Omeprazole            75.42           Budesonide             514.2
  Prednisone            43.4            Alfacalcidol           500
  Betamethasone         20.96           Mycophenolate          310
  Acetylcysteine        12              Filgrastim             289
                        2,158.87 (\*)   Insulin Lantus®        257
                        DU90%                                  28,265.76
  --------------------- --------------- ---------------------- -----------

NIS = New Israeli Shekels

(\*) DU90% cost= 20,263 NIS

###### 

Define Daily Dose (DDD), Drug Utilization 90% Index (DU90%) and Drug Cost 90% Index (DC90%) for Pediatric B.

  -------------------- --------------- ----------------------------- -----------
                       DDD                                           DC90% NIS
  Sodium Heparin       2102            Hyperimmune Gamma Globuline   13,717
  Salbutamol           1625.63         Budesonide                    4,370
  Folic Acid           501.63          Lactulose                     3,765
  Methylprednisolone   440             Arginine                      2,404
  Budesonide®          78.75           Methylprednisolone            912
  Morphine             72.08           Levonorgestrel                480
  Nifedipine           101.26          Enoxiparin                    353
  Prednisone           375             Nifedipine                    297
  Ibuprofen            49.17           Midazolam                     266
  Hydrocortisone       45.55           Glucose 5%                    235
                       5,391.07 (\*)   Dopamine                      223
                       DU90%           Salbutamol                    201
                                       Ondansetron                   200
                                                                     27,423
  -------------------- --------------- ----------------------------- -----------

NIS = New Israeli Shekels

(\*) DU90% cost= 6,269 NIS

In Pediatric A, salbutamol and clonazepam were the two most prescribed medications; while, in Pediatric B, sodium heparin and salbutamol were the most prescribed medications ([Table 3](#T3){ref-type="table"} and [4](#T4){ref-type="table"}).

No differences were depicted between the A and B units comparing the DU90% index. While, a net increment in medication cost (p=0.04) was registered according to the calculated cost from the depicted DU90% when the A (20,263 NIS) and B (6,269 NIS) admission units were compared.

Clonazepam (16,211 NIS) and glucose 5% (4,307 NIS) for the A unit and hyperimmune gamma globulin --IVIG (13, 717 NIS) and budesonide (4,370 NIS) for the B unit were the most expensive prescribed items during the study period.

DISCUSSION {#S4}
==========

In this descriptive - prospective point prevalence survey on general medication utilization pattern and cost analysis in two pediatric admission units located in a tertiary university medical center, it has been demonstrated that 94 and 88 of the surveyed individuals had at least one general medication exposure during the study periods for the A and B admission units, respectively. Salbutamol (835 DDD) and sodium heparin (2,102 DDD) were located at the head of the DU90% index list in the A and B units, respectively. Clonazepam (16,211 NIS) and hyperimmune gamma globulin (13,117 NIS) were located at the head of the DC90% index list for the respective admission A and B unit. It should be stressed that the hyperimmune gamma globulin was prescribed to only one child who suffered from Kawasaki disease.

A net increase in cost prescription attitudes was depicted when the A and B units were compared. (20,263.30 -- 6,269.22 NIS) (p=0.04). The A admission unit had lower prescription volume measured by the DU90% index with higher medication cost in comparison to the B admission unit who had higher volume with lower costs. Both admission units were comparable according to admission diagnosis, children mean admission days in hospital, total admission days during the study period and total children admitted for care to each unit.

Conroy et al.[@B10] studied 2,262 drug prescriptions that were prescribed to 624 children, 46% of all prescriptions were either unlicensed or off-label medications. In our study, using the prescription-point prevalence screening technique 187 different medications were prescribed in both admission units, 3 drugs were over the counter medications (aspirin 75 mg, paracetamol and ibuprofen) and 9 medications were off-labeled (allopurinol, amiloride, baclofen, milrinone, omeprazole, somatostatin, simvastatin, methotrexate and isoniazide) and none of the prescribed medications were unlicensed for the local legislation. There is not a wide market for many drugs in children, and drugs are expensive to be tested in this "special" population. For this reason, a number of drugs are used off-label in children, even though they might be of value in specialty practice.

In a recent publication by Zuppa et al.[@B1] it had been registered 61,916 encounters in one Philadelphia's children's hospital. Sodium chloride (9%), sodium heparin (7%), acetaminophen (5%) and albuterol (4%) were the four most prescribed medications.

The concomitant and extended utilization of two or more medications in a treatment, either due to the patient's pathology or the need for action or the use of synergistic effect, is known as polypharmacy. It is estimated that those interactions occurs in 3-5% of patients treated by up to 4 different medications, and when 10 to 20 drugs are used the rate reaches more than the 20%.[@B11] Martinbiacho J.[@B9] found a total of 6,857 drug interactions that corresponded to 1.9 interaction/prescription.

A mean of 8 and 10 different medications / child were registered in the A and B admission units, respectively; the high medication exposures/child jeopardize those children and exposed them to potential drug-drug interactions during their in-hospital therapy.

In hospitalized adult patients the incidence of adverse drug reactions (ADR) has been widely investigated[@B11]-[@B13]; while, in children and neonates there is lack of information. The risks factor for ADR in children include multiple drug exposure with potential drug-drug interactions, complex multisystem illness, age younger than 12 months and parent or prescriber increase in dose.[@B14]

The limitations of this study were: 1) clinical outcomes were not registered; 2) children age and gender were not stratified in the results analysis; 3) the main discharge diagnosis was not taken into consideration; 4) the developed adverse drug reactions were not registered; 5) OTC medications and off-level indications were not registered.

Interventional program should be instituted for better drug prescription and utilization. In institutions fortunate enough to have clinical pharmacologist and/or a clinical pharmacist consultation services it has been established that cooperative efforts among the medical and administrative staffs should lead to early and mandatory consultations for patients with multiple organ diseases or multi drug exposures who need innovative technologies.[@B8],[@B15] The consultant should be involved personally when new technologies are suggested, for example: human free salt albumin for the treatment of severe hypoalbuminemia due to diffused mucositis after bone marrow transplantation or hyperimmune gamma globulin (IVIG) together with alternative plasmapheresis for the treatment of acute vascular rejection after kidney transplantation or the use of IVIG in multi-bacterial infection and severe sepsis with multi-organ failure

It has been recommended 1 the creation of a local, national or even a global drug utilization network to facilitate the examination of geographical and /or socio-economic influences in drug utilization and prescribing practices in general and for children in special clinical settings.

CONCLUSIONS {#S5}
===========

A significant difference in the prescription number of general medications volume/patient (8.4-10.9; p=0.02) was depicted between the A and B admission unitsIncreased cost in prescription attitudes was depicted in the A unit in comparison to the B unit (20,263.30 -- 6,269.22 NIS) (p=0.04). The A admission unit had lower prescription volume with higher medication cost for the study period in comparison to the B admission unit.Interventional program should be instituted for better drug prescription, medications utilization control and cost containment including also the establishment of a consultation service staffed by a clinical pharmacologist and/or a clinical pharmacist.
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